Home / Transcripts / Demant A/S (DEMANT) · August 13, 2025

Demant A/S (DEMANT) Earnings Call Transcript

August 13, 2025

Nasdaq Copenhagen DK Health Care Health Care Equipment and Supplies earnings 62 min

Earnings Call Speaker Segments

Gustav Hoegh executive
#1

Good afternoon, everyone, and welcome to the conference call we're holding after the release of our revised outlook for 2025 and the interim report for H1 2025, which came out after market close yesterday. On today's call, we plan to go through a presentation and then hold a Q&A session, as we usually do. The presentation should be available on our website now. We expect the call to run no longer than 1 hour in total, Q&A session included. So please keep yourself to a maximum of 2 questions at a time. Thank you. Joining us today are Søren Nielsen, our President and CEO; René Schneider, our CFO; and myself, Gustav Hoegh from the IR team. That covers all the practical elements. And with that, I'll hand over to you, Søren.

Søren Nielsen executive
#2

Yes. Thank you so much, Gustav, and welcome, everyone. On today's agenda: business highlights, key financial takeaways, and sustainability advancements. After that, business area, with a bit more detail and color on that, before Rene walks through group financials, and I'll wrap up with the revised outlook, and then we move into Q&A. Business highlight for Demant in first half of 2025. Headline #1 is a global hearing aid market that grew below the normal 4% to 6% growth expectation. This is purely attributed to various elements of macroeconomic uncertainty and turmoil in global trade, et cetera, that have led to consumers being less hesitant to start wearing hearing aids or postponing their upgrades. In hearing aids, we saw good growth in unit sales, although growth was negatively impacted by mix effects that led to a lower ASP. This is purely attributed to market share gains outside U.S. and lower growth in U.S. that leads to a decline in our global ASP that outbalanced the growth coming from selling more units. Hearing Care grew in line with the market in first half with some growth deceleration from Q1 into Q2, partly driven by the current environment and consumer cautiousness. The effect was particularly in U.S.

Søren Nielsen executive
#3

I will say, though, that you should be careful not to read too much into it. There's always some timing and weather effects that land close in March or April. So I think the main thing to focus on is H1. Diagnostics kept being affected by unfavorable market trends, especially in the U.S., and by macroeconomic uncertainty as well, which has caused investments to be postponed — a good order book, but execution that came in below what was planned and what we'd expect under normal conditions. And yes, we see plenty of reasons why these things are being pushed somewhat further out in time. In June, as we already announced, we reached an agreement to acquire the KIND Group, one of the world's leading hearing aid retailers, with roughly 650 hearing clinics, mainly in Germany. Key financial takeaways from the first half, bringing all of this together: group organic growth of 0%, which is under expectations because of the hearing health care market growing less than normal and lower sales to a large U.S. retailer. Group gross margin fell 0.8 percentage points, a bit more than expected given the unfavorable geography and mix — geography mix shifts, particularly in hearing aids, which led to the reduction in our global average selling price that we already spoke about. OpEx, very strong control, and continuing the trend from last year.

Søren Nielsen executive
#4

What we observed was organic growth of only 1%, which reflects, yes, a run rate coming into the year that was lower than expected, along with our tight focus. Growth as reported came in at 4%, and acquisitions are the main reason for that. EBIT before special items reached DKK 1.849 billion. The EBIT margin before special items narrowed. Once again, we needed to move more units to generate the same revenue, and that had a negative effect on the profitability of the business. This again stems from unfavorable shifts in the geographic mix — meaning which countries we sell what in — and, as a result, operating leverage that fell short of plan. Even with lower profitability, we produced very solid cash flow — cash flow from operations of a little north of DKK 1.5 billion and free cash flow of DKK 1.126 billion. On the outlook, we have revised our expectation for the global hearing aid market from the previous 1% to 5% growth in value to 1% to 3% now. And our EBIT, given the geographic mix development, has been adjusted downward from the previous EUR 4.1 billion to EUR 4.5 billion to EUR 3.9 billion to EUR 4.3 billion now. The share buyback, as announced in June, was paused following the agreement to acquire the KIND Group. On sustainability progress in the first half, we have helped more people hear better.

Søren Nielsen executive
#5

The number of people using hearing aids from Demant has risen, and it's positive and reasonably in line with expectations. Our Scope 1 and 2 market-based greenhouse gas emissions are down 5%, as we've managed to raise our renewable electricity share by 5% — or grow the renewable portion and shrink the emitting portion — and that matches what we expected. The share of highly exposed employees trained in Demant's code of conduct has hit 94%, and we'll soon reach the 100% target. Moving to the business area review, beginning with the global hearing aid market in H1 as shown in the table: Q1 came in at 2%, with a very negative trend in the U.S. commercial market of minus 5% and VA at minus 1%. So North America overall was down 3%, and Europe was on the softer end of the usual 4% to 6% range. In the second quarter, though, we've seen things roughly in line with expectations — some normalization in the U.S. commercial market, the VA channel still soft, but Europe hasn't delivered the growth; despite strong growth in France, the rest of Europe hasn't met expectations, and we're seeing contraction in several markets, again put down to consumer caution stemming from macroeconomic uncertainty.

Søren Nielsen executive
#6

For the global market, ASP development is still expected to be negative at 1% for the half year. So once more, in value terms, at 2% growth for the first half year. And in Europe, France is expected to be strong. In NHS, growth was negative because of very strong comps, and excluding France and NHS, growth decelerated. It was still slightly positive in Germany, but downwards, and likewise for a number of other European markets. Growth in North America, as already mentioned, accelerated, while in Canada we saw a negative development in Q2, also driven by macroeconomic uncertainties. The rest of the world saw normal growth despite flattish growth in China and Japan. In Australia, growth was negative. We estimated that several export markets saw good growth. In Hearing Aids, we saw, again, unit growth in Q2 being strong. We clearly took a global share in market share in units. However, with a continued unfortunate development in the mix of geographies, growing outside the U.S. in total and in markets with less strong ASP, whereas we saw negative growth in both the U.S. — in the U.S. — and some of the European markets, Canada still delivered strong growth. Looking at the Hearing Care in the second quarter, yes, a slower momentum.

Søren Nielsen executive
#7

But again, don't read too much into that. Some of it also comes down to when orders were closed between the first quarter and the second. We're still seeing some difficulty attracting new users, and we put that down to ongoing macroeconomic uncertainty, which weighs on users and makes them more cautious — a bit more than usual, they've decided to push back their first hearing aid further, and some upgrades are also being stretched out. Growth came mainly in units, though we also saw a modest ASP increase, partly from geographic mix. France showed good growth, which sped up thanks to uptake in that market. Germany delivered strong growth. We're flagging Sweden here because of local regulatory changes. North America saw negative growth in the U.S. owing to consumer caution, but also, I'd say, partly the timing of order closings, and then Canada had negative growth because of unfavorable market development, while China posted strong growth, helped by an ASP tailwind, and Australia was slightly negative. Diagnostics in the second quarter faced continued headwinds from weak market developments, especially in the U.S. So growth slowed from Q1 to Q2, matching the market's growth rate, with growth held back by negative market development, particularly in the U.S.

Søren Nielsen executive
#8

Macroeconomic uncertainty meant equipment investment came in at a lower level. Once more, we just see orders getting pushed back and installed later than planned. Naturally, we hope and expect a rebound should there be more clarity regarding financial developments in the U.S. Europe: positive in France, somewhat negative in the U.K., with NHS again being a bit restrained when it comes to investing in new equipment, strong growth across several medium-sized European markets, and negative growth in the U.S., which is by far the largest factor, together with Canada and North America overall. And once again, Asia Pacific outside China is doing fine, but China remains affected by an insufficient range of Made in China products to take part in all government tenders. With that, I'll hand it over to you, Rene.

René Schneider executive
#9

Thanks, Søren. Let's begin with revenue for the first half year. We're reporting organic growth of 0%, and that came in below what we expected; the deviation from our most recent expectations was driven especially by softer-than-usual growth in the hearing health care market and by lower sales, particularly to a large U.S. retailer. Acquisitive growth added 3%, mainly from Hearing Care, though Hearing Aids also made a small positive contribution. Foreign exchange rates remain a headwind, at minus 1%, again due largely to unfavorable movement in the U.S. dollar. Gross profit for the first half year came in at just over DKK 8.5 billion, flat compared with the first half year of '24. Gross margin fell 0.8 percentage points against last year. We had anticipated a decline, given the particularly strong gross margin in last year's first half year, when we launched a high-end hearing aid product. Even so, this development was slightly worse than anticipated. The drop in gross margin stems mainly from ASP headwind in hearing aids, as already covered, along with a modest decline in the gross margin for Diagnostics.

René Schneider executive
#10

On the FX side, that also weighed a bit on gross margin. So if you look at our typical 76% to 77% gross margin range, you'll see we're sitting at the very low end of it. And looking ahead to H2, we'd also expect to land toward the bottom of that range. As for operating expenses in the first half, we kept a tight grip on those, which let us raise group OpEx by 1% organically — again, a reflection of the low run rate we carried into the year after last year's second-half cost-cutting push and our ongoing discipline on costs. Acquisitions contributed 4%, consistent with our acquisition strategy. And there too, you could say we're seeing a negative effect from FX. Perhaps a word here as well on the run rate going into H2. Our current estimate is that, looking at total reported operating expenses, they'll come in very close to what was actually reported in the first half. So on a sequential basis, no growth in the reported OpEx figure for the group — which shows our continued dedication to a strong cost-savings effort.

René Schneider executive
#11

One thing worth emphasizing is that in spite of this, we keep putting money into upcoming hearing aid launches. That leads us to EBIT before special items. For the first half year it came in at DKK 1.849 billion, down 11% versus the same period a year earlier, with an EBIT margin contraction of 2.3 percentage points. The EBIT margin before special items took a hit from market growth that was weaker than normal, from operating leverage that came in below plan as a result of that market growth, so to speak, and also from an unfavorable geographical mix. On top of that, exchange rates have a sizable effect on our group EBIT — roughly DKK 50 million in the first half year, most of it in the second quarter. That is, so to speak, an FX impact that will also carry into H2 at a similar level each quarter. We recognized no special items in the first half year. Then finally — sorry, not finally, but moving on to the cash flow side, it remains very strong; in fact, cash flow from operations grew slightly, by 1%, thanks to strong net working capital management. We keep investing CapEx in line with our mid- to long-term expectations of 4%. Cash out tied to acquisitions was just shy of DKK 850 million, for bolt-on acquisitions in Hearing Care, so very much in line with our strategy.

René Schneider executive
#12

Up until we paused our share buyback program tied to the deal to acquire the KIND Group, we repurchased shares totaling DKK 582 million. Now, a brief point on balance sheet items. It rose reportedly 1%, with 2% coming from organic growth, 3% from acquisitions, and minus 4% from FX. The major movements are, let's say, other current assets, largely driven by an unrealized gain on financial contracts stemming from our hedging activities. Net working capital fell by 3%, and gearing stood at 2.5% at period end, which sits inside our mid- to long-term target range of 2% to 2.5%. With that, Søren, I believe we've covered the outlook.

Søren Nielsen executive
#13

Yes. Thanks a lot, Rene. And once again, a lot of things haven't changed. But naturally, as we've already mentioned, we've needed to revise downward our forecast for market growth across the full year, which was previously 2% to 4%, though we're taking 1 additional percentage point of the units, and so we're reducing the value expectations to 1% to 3% <<inaudible>>, while keeping our outlook on the French market, which in units should still deliver high single digits in -- on track to deliver high single-digit unit growth for the full year. Cash set aside for acquisitions, as announced earlier, is above normal, and also the -- in the earlier statement, the announced acquisition of KIND. And then, yes, nothing further on that. And then once more, because of the unfavorable geographic mix shift and needing to sell more units to reach the same revenue, we've needed to reduce our full-year profitability expectations from previously DKK 4.1 billion to DKK 4.5 billion to now DKK 3.9 billion to DKK 4.3 million. I believe that's all for now. Let's move to the Q&A session.

Operator operator
#14

<<operator_script>> Our first question today is from Hassan Al-Wakeel of Barclays.

Hassan Al-Wakeel analyst
#15

I've got 2 questions, please. First, just regarding Costco: when we last spoke, Rene, you weren't anticipating significant share shifts in that channel, given Sonova's return, and you'd incorporated a degree of uncertainty into the guidance. Has that share movement caught you off guard and turned out to be more substantial? And do you believe it has now settled down? Second, could you give more detail on the trends we're seeing across major European markets? I realize you haven't explicitly mentioned any COVID anniversary impact, but do you consider that meaningful in certain markets where you operate? And in which European markets do you feel you're picking up share?

Søren Nielsen executive
#16

Yeah. Perhaps I could just add something to that question, even though it was partly directed at Rene. With that large retailer, our assumption was never that a whole extra supplier would come in. What we figured was that if anything shifted, one supplier would be swapped out for another. That isn't what happened. And yes, that has affected both what we saw in the second quarter and what we expect for our share in the second half in that channel. So it follows naturally from sales being split across a greater number of suppliers. As for trends across Europe, it's really hard to pin down precisely what lies behind the weaker demand we're seeing and the greater effort we now have to put into our Hearing Care business to bring in enough traffic. We put it down to general uncertainty, and then there are all sorts of things you can speculate about, like the renewal rate after COVID. We're somewhat cautious about that, because this usually plays out over a fairly long stretch, and it also depends on when you actually call on the group, since you can pull some things forward a bit, and so on. So we don't put much weight on that.

Søren Nielsen executive
#17

Still, pinning that down precisely is always tough, obviously. There has also been—and still is—a connection to the very hot summer in some European countries, and so on. Sure, if we zoom in on particular regions or particular markets, then yes, you can spot some of that. But on the other side, these sorts of things tend to catch up fairly fast. So when you view it across a full first half year, then what we saw in Q2 as well we mostly put down to caution among users and consumers plus broader macroeconomic uncertainty.

Hassan Al-Wakeel analyst
#18

That's really helpful. If I could just ask a quick follow-up about Costco: in your view, has the share shift settled down at this point? And what assumptions have you built into the guidance for the second half?

Søren Nielsen executive
#19

Yes. We tend to examine it across a longer stretch, and you have to keep in mind — these are bulk shipments, so there can be a lot of variation. On top of that, you get no visibility into the overall market or overall purchasing. So you make certain assumptions about what the customer consumes, and then over 1 to 2 months you check your own share. It's too soon to conclude whether things are stable or not. You'd need to watch trends across a somewhat longer window. But this reflects an updated view in which we take out, I'd say, a material share in the second half. If that weren't the case, we wouldn't bring it up.

Operator operator
#20

The next person to ask a question is Martin Parkhoi with SEB.

Martin Parkhoi analyst
#21

Martin Parkhoi probably more closer. But Martin Parkhoi, SEB. Just a quick follow-up on Costco, though leaning more toward profitability. You lowered the midpoint of your EBIT guidance by DKK 200 million. And I'm fairly certain operational leverage is quite high in Costco. So could you maybe — I get that you won't give the full number, but if we take that DKK 200 million split, how much of it comes from the weaker market and how much actually comes from the lowest operational leverage in Costco? And then a second question, just on the — what you think — you put out in the report where you mentioned the impact from future product launches on production cost and OpEx in the second half. Two questions on that. Have there been any changes to that cost assumption during 2005 since you put it out now? And is this higher than normal? What should we read into that? And why do you actually put it out there?

Søren Nielsen executive
#22

Yes. Thank you. I’m not sure, Rene — would you like to say something about the...

René Schneider executive
#23

If you break down the midpoint of that profit adjustment, essentially it comes down to two-thirds from the market and one-third from Costco, partly offset by — you could say — an even stronger focus on the OpEx side, which might counterbalance some of that effect. That gets you to DKK 200 million. And regarding OpEx, well, you could say these are activities we had planned throughout the year. So at least it hasn't materially changed in the second half year versus what we originally expected. It's just important to stress that even with the cost-side efforts we're making, that doesn't mean we're unable to fund and carry out the activities tied to future hearing aid introductions.

Søren Nielsen executive
#24

Of course, that also marks a contrast with last year, when those kinds of events weren't happening, unlike this year. So the significance really shows up in the year-over-year comparison.

Operator operator
#25

The next person to ask a question is Veronika Dubajova with Citi.

Veronika Dubajova analyst
#26

I'll stick to 2, please. First, maybe just try to revisit any commentary you can offer about what you're seeing in the markets as you look at July and August. I'm not seeking commentary on your performance, but obviously, in the regions where you do have monthly data, I'm curious whether you could comment on whether July volumes are improving, staying stable or deteriorating. And in particular, I guess I'm curious about the U.S., Germany and France to the extent that you see those numbers. And then I'll ask my follow-up after that, if that's okay. I'll let you answer that first.

Søren Nielsen executive
#27

We’re going to stay cautious about a single month, and we don’t see any meaningful variance from what we just described for the second-half assumption. So everything appears consistent with that.

Veronika Dubajova analyst
#28

That's useful. Then perhaps just regarding the spend on product launches — and I understand you'd rather not disclose much. Still, if I compare the typical sequential OpEx run rate from the first half to the second half against what you're guiding for this year, it does suggest a significant investment in product launches, which isn't usually typical for the industry unless major product introductions, new platforms, and so on are happening. So could you perhaps walk us through some of the expenditures we should expect in the second half, and why you believe it's necessary to invest so heavily at this point?

René Schneider executive
#29

Okay, Veronika, to lay out the assumptions, let’s frame it for the second half of the year. What we’re referring to is OpEx showing no sequential growth. So the actual reported OpEx you see for the first half is roughly what you should expect us to report in the second half. In other words, sequentially it’s flat. Of course, year-over-year it will show growth, because, as you could put it, we made a massive cost-saving push in last year’s second half. So organically you’ll see mid-single-digit growth year-over-year. But on a sequential basis, as a group we won’t spend more in the second half than we did in this year’s first half — just to be precise about that.

Veronika Dubajova analyst
#30

Sure. Could you walk us through some of the things you plan to be doing in support of the product launches you're thinking about?

Søren Nielsen executive
#31

They’re naturally the kind you get whenever you do product launches, which is what we always do. That means customers running sales and marketing efforts, plus assorted launch expenses. Don’t take this to mean they’re much different from what you’d typically expect—it’s simply the contrast between, as Rene put it, a very tight budget or spend in the second half of last year and this year, and that’s exactly what we called out.

Operator operator
#32

And our next question is from Maja Stephanie Pataki at Kepler.

Maja Pataki analyst
#33

If we zoom out for a moment and consider how the market has grown, it's been somewhat volatile across the past several years. And naturally, the level of uncertainty has been enormous. First came COVID. Then we had inflation. Now we're facing difficult political circumstances involving the U.S. tariffs and all of that. So this uncertainty we've experienced over the past couple of years—at least for the time being—we have to treat it as permanent. How do you approach planning over a 3-year horizon? Do you think that perhaps, since market growth isn't a simple 4% to 6%, with very large differences between markets, you need to adopt a different approach to how you operate in markets? And as a follow-up to that, what's your thinking on the cost side? Because, I mean, when you look at your margin trajectory over the past couple of years, it wasn't too exciting. So do you think it might be time for a more thorough restructuring effort to lift margins?

Søren Nielsen executive
#34

Yes. Thanks so much, Maja. I completely agree that volatility has risen quarter to quarter and half year to half year versus what we saw previously. Yet either way, we've also witnessed quarters and half years delivering really strong growth soon after a decline. So it matters too that you're still around and prepared for when the market picks up again. Thus we don't view the fundamentals as having shifted. That said, yes, there's more volatility and more dynamics. Still, when it comes to the market's absolute size, we'll see narrower swings around a fairly steady line. On your question's second part, it naturally, as always, requires continuously hunting for cost efficiencies, which is what we do when we just pointed to a modest 1% organic growth in a world full of inflation. That happens because we adopt a somewhat different approach and do more than perhaps was done previously to soften these effects. So we don't wind up cutting what must be done on the sales side, on the R&D side, et cetera, but naturally, we seek scale effects and cost efficiencies wherever we can. And naturally, you might also say that, looking ahead, we certainly also consider further opportunities to build and win back some of that lost margin.

Søren Nielsen executive
#35

We obviously still want to operate this business at a better margin than what showed up in the first half, and in that period you also saw a market that came in below expectations.

Operator operator
#36

The next person to ask something is Graham Doyle with UBS.

Graham Doyle analyst
#37

I have two questions. First, regarding those costs tied to future product developments. I believe we've talked before about how a product launch would typically happen in H2. And clearly, nothing has come yet. So it would help to clarify one specific point — when you consider the philosophy behind launching a product, historically the idea, especially for the platform, has been to launch with enough time to get into the VA. So could you tell me whether that approach has changed? Or would you still aim, if you were launching some kind of platform, to make sure you hit the VA window?

Søren Nielsen executive
#38

I'll put it in general terms. Yes, we still intend to carry out 2 major launches per year, whether those are platform or non-platform products. That's what we're planning for this year as well. And of course, the precise timing always depends on how ambitious the scope is, on finalization, and on making sure everything is genuinely ready and ramped up, and so forth. Trying to hit the VA window is always desirable. It isn't always achievable. Our guiding principle is that we announce new products once they're ready for sales, since we want to avoid any potential holdback in the existing business until we can genuinely introduce and deliver to customers. The same holds for this half year. So yes, we remain committed to launching 2 times per year. And yes, we have a solid pipeline for this year as well as the years ahead. <<inaudible>> Operator, can you hear me? Hello, operator, any -- are we getting through? Hello, operator <<inaudible>> can you hear me?

Operator operator
#39

I can hear you. Can you hear me?

Søren Nielsen executive
#40

Yes. We hear you.

Operator operator
#41

Okay, that sounds good. I’m able to rejoin this line now. I can hear my own voice coming back with a slight echo, though it appears to have improved at this point. Are you still able to hear me?

Søren Nielsen executive
#42

That's just an echo. There's a slight hum coming through, but nothing beyond that.

René Schneider executive
#43

We have actually stepped away from the call at this moment. Could you <<inaudible>> so that we are talking privately.

Søren Nielsen executive
#44

That's not our view. Our data doesn't suggest that. Should we move on to the next — operator, please take the next question.

Operator operator
#45

Okay. Give me a second while I reconnect to the call. The conference operator here — the speaker line has been restored. So, Mr. Doyle, go ahead with your question.

Graham Doyle analyst
#46

Okay, so to pick back up on my earlier point: in the past you've laid out that new product launches usually happen in the back half of the year, and we're now in that back half. In this document you've mentioned higher costs related to investing in new products. What I'm really asking is this — your approach has historically been to place new products into the VA channel, since it's a key channel. Should we still reasonably expect that going forward?

Søren Nielsen executive
#47

Graham, I hear you. You've made your point.

Graham Doyle analyst
#48

Alright, please proceed.

Søren Nielsen executive
#49

Sure, I’ll give the answer again, and then we can move on to your second question. I’ll keep it simpler this time given the time constraints. We remain dedicated to carrying out 2 launches each year, and we’ll do so this year as well. Our pipeline is solid and strong because of the risk that customers are delaying decisions on existing orders. We announce new products once they’re ready for sale and have been ramped up adequately, and that’s going to apply in this instance too. Naturally, it’s always better to aim for a window such as VA, though that isn’t always possible, and I’m unable to say anything more about launches falling short this time. What’s the second part of your question?

Operator operator
#50

Gentlemen, it looks like Graham has taken himself out of the Q&A. So we’ll go on to the next one. Perhaps Carsten from Danske Bank.

Carsten Madsen analyst
#51

Carsten from Danske Bank here. I’m not sure—I really wasn’t able to hear.

Søren Nielsen executive
#52

Got it, Carsten — we hear you. Please go right ahead.

Carsten Madsen analyst
#53

Carsten from Danske Bank here. I've just got one question about what's left of this year. You posted 0% organic growth during the first part of the year. And if we look at the midpoint of your guidance — let's say 2% for the full year — that means you need a pretty substantial rebound in the second half. So which of your divisions or franchises do you expect to respond first? Would it be wholesale, diagnostics, retail, and so on? And could I also get something like a confirmation — or what should we call it — that Diagnostics will remain under pressure for the remainder of the year? Or how do you see Diagnostics?

Søren Nielsen executive
#54

Yes. Thanks, Carsten. I'll try to give you the big picture. Of course, it'll mostly just come down to scale, and that's being propelled by Hearing Aids and Hearing Care. There's something in the comps on both sides. Once again, we had quite a few items in Q1. During the second quarter, we've recorded solid share gains worldwide. So naturally, we're facing that headwind in the U.S. business, which comes from a large retailer. Beyond that, though, momentum in the business has generally been good. That, along with some market improvements relative to the first half, is the key reason. Diagnostic is somewhat more uncertain, and it ties to, you might say, a higher level of investment in the U.S. and precisely when that lands — we really can't say. So I won't get too specific about the individual outlook or the growth expectation for each business. But it has to be driven by Hearing Aids and Hearing Care, and it will be.

Operator operator
#55

The next person to ask something is Niels Granholm-Leth with DNB Carnegie.

Niels Granholm-Leth analyst
#56

Starting with my first question, can you identify any impact from that 5-year COVID shutdown that Amplifon mentioned during their conference call? Second, given that you expect to complete the KIND acquisition around the start of quarter 4, could you discuss what you anticipate for net financial items across the full year?

Søren Nielsen executive
#57

I’ll take the first one. I believe I touched on it a bit earlier—not sure whether you caught that. Naturally, we can observe that in certain months, including some during Q2, the database contained fewer prospects that had been fitted there. But people don’t all simply arrive at once. So if you look at how things are actually distributed, we don’t assign much weight to that effect. It may play some role, but in our view, yes, macroeconomic uncertainty is much more significant. So no, we don’t place much emphasis on that. You can also look at particular regions and smaller areas, and you can certainly observe some impact from weather and so forth, but it usually rebounds quickly. So a strong hearing aid market in the first half.

René Schneider executive
#58

Yeah. Regarding net financials, Niels, what we're currently anticipating for the full year is a bit worse than last year, due to increased debt and expansion in our retail business as well, though this is partly offset by reduced interest rates. We haven't included any assumptions about or from KIND—not in financials, nor in EBIT or sales—because we lack clarity on when the transaction will close. Once that becomes clear, though, we'll revise our outlook to reflect it.

Operator operator
#59

Martin Brenoe of Nordea has our next question.

Martin Brenoe analyst
#60

Martin Brenoe here from Nordea. So I want to get a clear picture of the retail division within Hearing Care — you've had considerable exposure to markets that are genuinely expanding, France, Germany, and the U.S. also being up. Could you perhaps expand a bit on whether the sluggish growth in Q2 is simply a matter of phasing, or whether there's something worth flagging? And related to that, you made some remarks about the market slowing toward the end of the quarter. Is that likewise what you're observing at the start of Q3? That's my first question. Then I'll hold my second one.

Søren Nielsen executive
#61

Thank you, Martin. I believe we really need to look at this on a country-by-country basis. France performed well, with uptake in that market coming in as expected. We track that within our own business. Germany was among the areas contributing to the softer growth and the below-forecast expansion in Europe on the market side, yet we performed strongly there specifically. The U.S. market also expanded in line with expectations. We simply didn't capture as much of that as might have been anticipated. In the U.S., I'd chalk part of it up to the timing of activities—when you close deals—and the amount of pipeline you're carrying into the following month, and so forth. So for the U.S., yes, a weaker showing that was isolated to Q2. On the other hand, there was also a better-than-expected showing in Q1. And when you view it across the first half, the U.S. business still represents an improvement relative to what we've witnessed in recent years, with nothing worth flagging as concerning, though sequentially, between the 2 quarters, it was a bit out of sync. Still, for the half year, I'd describe it as in line with expectations.

Martin Brenoe analyst
#62

All right, that's quite clear. Then, just to follow up, I suppose you've noticed generally on this call that everyone and their mother are wondering if you might launch a product sooner rather than later. Do you think you've also observed some retailers holding back somewhat because they anticipate new products arriving?

Søren Nielsen executive
#63

No, I'd say those rumors don't carry much weight in the market. They're especially more pronounced within the investment community.

Operator operator
#64

The next question is from Oliver Metzger at ODDO BHF.

Oliver Metzger analyst
#65

First, on the broader softness in the hearing aid market — Maja also probed this area. If I recall correctly, a station roughly 3 years back concerned repurchases, where we noticed some delays. You also mentioned then that first-time users were showing a bit of hesitancy. So could you start by breaking down the decline between first-time users and repurchases? And then, zooming out, the hearing aid market overall appears to have grown more volatile over decades. You spoke of very high stability even through COVID and the inflation episode a few years ago. Now it clearly leans more on consumer confidence. So it would be great to hear what has shifted in market fundamentals such that certain external factors matter even more than before? And the other one is very quick on China — the ASP tailwind you reported in Hearing Care, more background on that, and how long do you expect it to last?

Søren Nielsen executive
#66

Yeah. Thanks a lot. When you look at first-time use versus upgrades, it's really hard to guarantee you're making an apples-to-apples comparison, because the question is how much effort went into each. What we're able to observe is that generating enough traffic of new — first-time users — into the business requires more effort. Doing that is always more expensive than reaching out to your database. Yet at some point, even if you can squeeze a little extra from the database, you have to return to first-time users. So the absence of market growth feels like it comes more from a shortage of new users, since that's the harder path. But honestly, I'd say both effects are present, and separating them is difficult. Still, we clearly perceive that postponing your first interaction and contact is very easy when someone reaches out to you about a first hearing aid, and that's plainly a factor here in the first half that we've observed. And in Europe, it's stronger here in the second quarter than it was in the first quarter. As for the volatility, I don't believe the fundamentals have shifted. I truly don't. I simply think the number of events that could set it off has been far more frequent.

Søren Nielsen executive
#67

We usually discussed the financial crisis as happening 10 years ago or 5 years ago, and after that it took another 5 and 10 years before anything truly significant occurred. We're also aware it needs to be something that in some way affects our core audience, senior citizens. So it isn't unemployment rates. It isn't annual salary trends and things of that nature. It's typically U.S. share price performance. And we can see again this time that it tracked that quite closely. And then in Europe, since there's more reimbursement, it arrives a bit later, but it sort of settles in more psychologically than it genuinely is financially — that things are somewhat uncertain and there's a war going on and now there's also a conflict in the Middle East and so forth. And that just somehow takes hold. And then in certain countries, tight government budgets can occasionally also result in longer waiting lists, things of that kind. But I don't believe any of the fundamentals have shifted. The frequency of these events is simply higher. And then China and ASP, it stems from — China is a nation with no professional education. And the more we put into training and education, the better results we achieve in selling higher quality devices to people.

Søren Nielsen executive
#68

That's something we've worked hard at, and it's paying off. The reason is that we keep moving upmarket in China, and the training level of hearing care professionals there is not as high as what we encounter in most other developed markets globally.

Operator operator
#69

Andjela Bozinovic from BNP Paribas has our next question.

Andjela Bozinovic analyst
#70

Let me start with the U.S. market. Could you speak specifically about managed care? How are you progressing in terms of share within that channel, and particularly with UnitedHealth? Then the second part of my question is again about Costco. If I recall correctly, you held the leading position in that channel before Sonova returned. Is that still true today, or are you experiencing a larger loss of share?

Søren Nielsen executive
#71

Yes. Thank you for your two questions. And as has been made public, we did alter our offering — our product lineup — specifically, yes, with regard to United. Beyond that, we don't discuss specifics of particular plans and accounts. But on the whole, yes, it's positive. We saw our share grow during Q2. And that's also part of, you could say, the share gain outside large retail in the U.S. that we observed moving from Q1 into Q2, and it forms part of the momentum we're carrying into the second half. On the larger retailer specifically, we believe — though we don't know — that we are the biggest player. We continue to believe that's the case. I'm merely noting that when there are 4 instead of 3, you'll see everyone losing some share. And I can't say that any one has lost more than the others. We still have a good, strong business, but it's lower than it was a year ago.

Operator operator
#72

Susannah Ludwig from Bernstein has our next question.

Susannah Ludwig analyst
#73

I've got 2, please. So I guess you mentioned picking up unit market share during Q2, on both a sequential and a year-over-year basis. But is it reasonable to think that this mostly came from geographies with lower ASPs? Because it seems like external growth in Europe -- in the U.S. and Europe was still negative compared with unit growth in those markets? Or was there also some kind of negative ASP effect within these geographies that's kind of pushing your unit growth closer to the market there? And then second, could you give a bit more clarity on the sort of negative wholesale performance in the U.S. even though the U.S. market rebounded to plus 4% in the quarter. I guess how much of that came from the Costco headwind? And what other factors drove the sort of underperformance relative to what we see as sort of U.S. commercial market growth?

Søren Nielsen executive
#74

Yes. Thanks a lot. You're completely right. The regions where global ASP is below average are the ones showing the strongest growth, and that's why our ASP has declined. There are significant variations among European markets, if that answers what you asked. France, for instance, is performing well for us, but the product mix there is also declining, since a lot of the people coming in for renewal choose a free-to-client category of hearing aids. At the wholesale level, those are priced substantially lower than premium products. As a result, ASP in the French market falls. That doesn't mean fewer people receive a premium product in absolute terms, but the bulk of market growth is occurring in the free-to-client category. So to sum it all up, yes, unit growth beating market growth in Q2, with ASP down because of geographic mix — that's exactly right. The U.S. outside large retail is a solid story as we move from Q1 into Q2. We've seen — you just — the question about managed care was just raised. That's one example of share gain. We've also seen a nice sequential share gain from Q1 into Q2 with the independents, and we view that as evidence of the strength of our product range following numerous competitor introductions that have been trialed out.

Søren Nielsen executive
#75

So that's the mechanism — a lot of customers sample the new offerings. After that, you observe how they respond. We feel good about the rebound that showed up in Q2. There's still a modest year-over-year decline, yet a solid improvement moving from Q1 to Q2. So again, that's momentum we're carrying into the second half. And the last channel in the U.S. is VA, where we saw some year-over-year growth in share right up until competitors launched new products. At that point you naturally see trial as well. We don't know how it plays out once things have more or less settled. But there too, we have seen — and continue to see — some of the accounts or locations that experimented with new products come back to Oticon Intent specifically, which continues to perform very well in VA and with independent dispensers. So the shortfall, if you want to call it that, in the second quarter in the U.S. can only be attributed to large retail.

Susannah Ludwig analyst
#76

And in Q2, does ASP take any hit in the U.S.? Or is it more like, say, in the independent channel, where ASP is flat? Or is there any negative ASP effect in any of those channels?

Søren Nielsen executive
#77

No, everything there is quite steady. It's also a mix shift inside the U.S. So really, you could say that when we expand versus Q1 on the independent side while giving up some ground in large retail, our U.S. ASP rises. So with so many channels and geographies, what it ultimately comes down to is a product mix effect, and that's what makes up the ASP. So it's fairly dynamic even inside a single market parameter, based on the actual sales mix you have.

Operator operator
#78

Robert Davies of Morgan Stanley has our next question.

Robert Davies analyst
#79

First, about France: you mentioned high single digit unit growth for 2025. Are we already running at that pace, or does your plan assume more acceleration across 3Q and 4Q? That was my first question. The second concerns how well your competitors' AI-enabled hearing aids have done. What feedback are you getting on which main features worked and which didn't, and what do you think you could still add through new product introductions? There's already speculation about what you might bring to market. I'm curious how you'd describe the excitement level among audiologists and their willingness to take on another potentially AI-enabled hearing aid.

Søren Nielsen executive
#80

Right. Regarding France, adoption is picking up gradually through the first half and also in Q2. So because of that alone, second-half growth is going to exceed the first half, and we still haven't reached the run rate we expect. On AI, I want to point out that we brought the industry's first AI-driven technology to market and we continue to regard ourselves as being among the absolute leaders there. What kind of signal processing you perform, what kind of battery you carry, and whether things run continuously or are something you use a little bit in special situations — there's a very strong correlation among those. Our strategy and approach is to ensure it's always doing a job in making sure you manage the dynamic listening environment you're in. The user doesn't have to switch anything on and off, and it doesn't compromise the size of the devices. And that's clearly the echo we hear from customers — that when it comes to end user satisfaction, solving hearing and noise, solving everyday life, our Oticon Intent, based on the AI algorithms we have, does a fantastic job.

Operator operator
#81

And with that, ladies and gentlemen, today's Q&A session is coming to a close. I'd like to hand the conference call back to Gustav so he can offer any closing remarks.

Gustav Hoegh executive
#82

Thanks, operator, and thanks to everyone for being with us on this afternoon's call. We're really looking forward to meeting plenty of you during the roadshow over the next few weeks. Should you have any questions afterward, feel free to contact the IR team directly once this call ends, and naturally we'll do everything we can to assist. Have a great day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Demant A/S transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Demant A/S earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.